An Explorative Study Of The Tolerability Of SU011248 In Combination With Docetaxel And Trastuzumab As First-Line Treatment In Patients With Breast Cancer Over-Expressing HER-2.
Phase of Trial: Phase I
Latest Information Update: 12 Aug 2016
At a glance
- Drugs Sunitinib (Primary) ; Docetaxel; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Pfizer
- 01 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Aug 2011 Planned End Date changed from 1 Aug 2011 to 1 Sep 2011 as reported by ClinicalTrials.gov.
- 07 May 2011 Planned End Date changed from 1 Mar 2011 to 1 Aug 2011.